 The Japanese Phase 3 Open Label Study assessed the safety and immunogenicity of herpes zoster subunit candidate vaccine, HZ-SU, administered through subcutaneous, SC, or intramuscular, IM. Roots in adults aged greater than or equal to 50Y. Vaccine response rates were 100% for both groups, with anti-G antibody GMCs of 44,126.1 MIU ML and 45,521.5 MIU ML in the SC and IM groups, respectively. Injection site reactions were common, with grade 3 redness and swelling more frequently observed after SC administration. Fatigue and headache were the most commonly general symptoms for both routes of administration. 10 unsolicited AES were reported in the SC group, while 7 were reported in the IM group. 2 unsolicited AES were considered related to vaccination by the investigator, and 3 non-fatal SAEs unrelated to vaccination were reported during the study. Overall, HZ-SU vaccine candidate resulted in a substantial immune response that was comparable between SC and IM subjects, but local reactogenicity may be greater for SC. This article was authored by Peter Vink, Masanari Shiramoto, Osayuki Ogawa, and others. We are article.tv, links in the description below.